GSK to produce 1bn doses of Covid-19 vaccine booster next year
Published By : Sourabha Parida | May 28, 2020 8:15 PM
Share
London, May 28: Pharmaceutical giant GlaxoSmithKline on Thursday said it plans to produce 1 billion doses of coronavirus vaccine adjuvant, an ingredient that makes vaccines work better, in 2021 to support multiple Covid-19 vaccine collaborations. Saying that it has started manufacture of the adjuvant at risk, the company added that it was in discussions with governments and global institutions about funding for production and supply of the adjuvant. "We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so," Roger Connor, President, GSK Global Vaccines, said in a statement. "We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple Covid-19 vaccines. "With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19," Connor added. GSK has formed several collaborations, including with scientific partners in North America, Europe and China, to develop vaccines, the company said, adding that discussions with potential partners on further collaborations are ongoing. In the last flu pandemic, GSK's pandemic adjuvant showed ability to reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people. Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections. GSK has prioritised its efforts towards making its pandemic adjuvant technology available to partners developing promising Covid-19 vaccine candidates that are suitable for use with an adjuvant. Confirmation of the enhanced manufacturing capacity follows completion of a review conducted across the company's global supply network. GSK said it will manufacture, fill and finish adjuvant for use in Covid-19 vaccines at sites in the UK, US, Canada and Europe.(IANS)
Prameya English Is Now On WhatsApp Join And Get Latest News Updates Delivered To You Via WhatsApp
You Might Also Like
More From Related News
Odisha: Youth lead the way in ‘Menstrual Health Awareness’ at Berhampur University
AIIMS Bhubaneswar ranked 2nd best emerging medical college in India
Health Minister reviews Dengue, Malaria, Diarrhea, and Jaundice, orders for proactive measures
Diarrhea outbreak in Odisha under control: Health Minister
Food Safety Crackdown in Bhuban: Stalls Sealed and Fined Amid Public Health Crisis
International Yoga Day 2025: History and significance
OMC Launches Major Sickle Cell Anemia Awareness Drive in Odisha's Mining Belts
Diarrhea outbreak in Jajpur triggers panic; Six hotels sealed
Odisha: Expert teams deployed to tackle Diarrhoea outbreak in three districts
Odisha: Health Minister reviews Diarrhoea outbreak, urges rapid action
Odisha battles Diarrhoea outbreak; Minister Suraj Suryavanshi reviews situation in Jajpur
AIIMS Bhubaneswar to be accorded Centre of Excellence Status for Sickle Cell Disease Management
"From Research to Practice": GSICON 2025 Aims to Revolutionize Geriatric Medicine in India
Odisha Govt intensifies diarrhea prevention measures across five districts
Orissa High Court halts Asst. Prof Recruitment at AHPGIC Cuttack citing irregularity
Odisha: Diarrhoea outbreak in Cuttack, 64 infected, one dead
Odisha Yatri App to soon offer ambulance services: Minister Bibhuti Bhushan Jena
Brain Fog Explained: Why You Can’t Focus and What Your Body Might Be Telling You
Odisha: Health secretary reviews diarrhoea management efforts in Jajpur
Odisha: Death toll in Jajpur's diarrhoea & cholera outbreak rises to seven after two more deaths